Ohio Department of Medicaid (ODM) Drug Utilization Review (DUR) Board Quarterly Meeting
May 11, 2021

The ODM DUR Board meeting was called to order at 12:03 PM EST via GoToMeeting
https://attendee.gotowebinar.com/register/4124977711676393740
Stacey Rexrode-Brewer, Pharm.D. presided

The following Board members were present: Scott Baran, R.Ph. David Brookover, R.Ph.
Michael Dietz, D.O.
Michael Farrell, M.D., Co-Chair
Robert B Kubasak, R.Ph.
A. Mehran Mostafavifar, M.D.
Lenard G. Presutti, D.O.
Stacey Rexrode-Brewer, Pharm.D., Chair
Donald Sullivan, Ph.D., R.Ph.

Also present from ODM were Donald Wharton, M.D., Michelle Barger, Pharm.D., Sean Eckard, B.S. Pharm.D., Tracey Archibald, Pharm.D., Yana Doughty, Pharm.D., Brian Gallow, Pharm.D.
Change Healthcare attendees included Jill R.K. Griffith B.S. Pharm.D., Gail Master, R.Ph., and Philip Verret, Pharm.D.
Approximately 42 observers were present.

The Conflict of Interest Statement

Signed 2021 Conflict of Interest Statement was received from each DUR Board member in advance of the meeting. The Conflict of Interest Statement was reviewed with the Board.

Roll Call and Review of Previous Minutes

The February 9, 2021 DUR Board meeting minutes were approved.

DUR Committee Report

G. Master presented the re-review results from the influenza vaccine fax to pharmacies. The fax resulted in an additional 44% of members receiving a vaccine in the subsequent influenza season.
Next, G. Master presented the proton pump inhibitor (PPI) deprescribing intervention and responses. Prescribers whose patients were identified as taking a PPI for longer than 6 months were educated on the potential adverse events associated with long term PPI use. They were also asked to reassess the indication for and duration of therapy.
She then presented the intervention and responses from prescribers whose patients were receiving opioid medications exceeding 80 Morphine Equivalent Doses (MED) per day. Prescribers were educated on pain treatment agreement requirements and asked to consider multimodal treatment strategies. Additionally, prescribers were reminded when to offer a prescription for Narcan.
Next, G. Master presented the intervention and responses from prescribers whose patients were taking triple antithrombotic therapy (TT) for greater than 30 days. Similarly, prescribers were asked to assess the indication
and duration of therapy, ensure a specialist was involved in patient care, and were educated on the increased risk of bleeding with prolonged TT use.

She then described a monthly outreach program which contacts prescribers and pharmacists whose patients are concomitantly taking medication assisted therapy (MAT) with opioids or benzodiazepines in the previous month. Providers are asked to acknowledge the medication combination and educated on OARRS requirements when prescribing and dispensing the medication. The prescriber and pharmacist responses were presented.

Lastly, G. Master provided an update to the Board on Coordinated Services Program (CSP) membership. There are currently 179 fee-for-service members enrolled in the program.

Health Plan Policy Update

S. Baran presented the ODM health plan policy update. Last month, ODM Director Maureen Corcoran announced the selection of six health care organizations to lead the department’s evolution of managed care services for its more than 3 million members and thousands of medical providers. ODM’s next generation managed care selection, contingent upon the signing of contracts, will begin covering members in early 2022. Members will continue to receive services with their current plans through the transition period and will have the opportunity to select a new plan through an open enrollment period beginning in late summer 2021.

At the last DUR Board meeting, S. Baran explained that enrolled pharmacies may submit electronic NCPDP claims for COVID-19 vaccine administration. Since then, CMS announced increased Medicare payment for COVID-19 vaccine administration. Beginning with dates of service on March 15, 2021, ODM will reimburse $37.98 for each dose of vaccine administered. ODM, Change Healthcare, and the managed care plans have been proactive in ensuring access to COVID-19 vaccines during the public health emergency.

Also announced at the February meeting, ODM began enrolling and reimbursing pharmacists as Medicaid providers. Currently, 560 pharmacists are enrolled. These enrolled pharmacists represent a diverse range of practice settings including independent practitioners, retail/community pharmacy, hospital and health system pharmacy, and ambulatory care.

Next, the Board was updated on recent P&T Committee changes. During ODM’s April P&T Committee meeting, a new category for narcolepsy drugs was added to the Unified Preferred Drug List (UPDL). Business discussed during the April meeting will go into effect July 1, 2021.

ODM has also announced Myers and Stauffer as its pharmacy pricing and audit consultant (PPAC), formerly known as the pharmacy operational support vendor. Myers and Stauffer will be responsible for determining reimbursement methodologies, conducting dispensing and ingredient acquisition assessments, and maintaining accurate and up-to-date pharmacy rates.

Lastly, S. Baran announced that two new pharmacists have joined the ODM Pharmacy Team.

Unfinished Business

There was no unfinished business.

New Business

G. Master presented an educational intervention faxed to pharmacies requesting pharmacists demonstrate the correct inhaler technique to Ohio Medicaid patients when dispensing an inhaler. The goal of the fax was to have pharmacists assess patient inhaler usage and maintenance technique, thus leading to patient education and a decrease in uncontrolled respiratory disease.

Lastly, Dr. Eckard provided an update on the reimbursement rate to pharmacies for the COVID-19 vaccine. A discussion ensued about the rates of vaccination in the Ohio Medicaid population, and methods to proactively increase this rate in the community.
Announcements

The 2021 calendar was reviewed. The RetroDUR intervention for May will focus on children who are taking opioids. A discussion ensued about the circumstances in which opioids are indicated in the pediatric population. There was also discussion regarding parameters which should lead to a targeted intervention.

The dates for the 2021 DUR Board meetings were reviewed:
• September 21, 2021
• November 9, 2021

S. Baran informed the Board that it is unknown whether the September meeting will be virtual and will keep the Board informed of updates.

Adjournment

The meeting was adjourned at 1:12 PM.